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ABSTRACT  31	  
This work reports for the first time the direct electron transfer of the Canis familiaris cytochrome 32	  
P450 2D15 on glassy carbon electrodes to provide an analytical tool as an alternative to P450 33	  
animal testing in the drug discovery process. Cytochrome P450 2D15, that corresponds to the 34	  
human homologue P450 2D6, was recombinantly expressed in Escherichia coli and entrapped on 35	  
glassy carbon electrodes (GC) either with the cationic polymer polydiallyldimethylammonium 36	  
chloride (PDDA) or in presence of gold nanoparticles (AuNPs). Reversible electrochemical signals 37	  
of P450 2D15 were observed with calculated midpoint potentials (E1/2) of -191±5 and -233±4 mV 38	  
vs Ag/AgCl for GC/PDDA/2D15 and GC/AuNPs/2D15, respectively. 39	  
These experiments were then followed by the electro-catalytic activity of the immobilized enzyme 40	  
in presence of metoprolol. The latter drug is a beta-blocker used for the treatment of hypertention 41	  
and is a specific marker of the human P450 2D6 activity. Electrocatalysis data showed that only in 42	  
the presence of AuNps the expected α-hydroxy-metoprolol product was present as shown by HPLC.  43	  
The successful immobilization of the electroactive Canis familiaris cytochrome P450 2D15 on 44	  
electrode surfaces addresses the ever increasing demand of developing alternative in vitro methods 45	  
for a more detailed study of animal P450 enzymes’ metabolism, reducing the number of animals 46	  
sacrificed in preclinical tests. 47	  
 48	  
 49	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1. Introduction 57	  
 58	  
In view of the huge numbers of animals used during preclinical tests in drug discovery [1], both the 59	  
European Union (European Commission and European Parliament, Directive 2010/63/EU) [2-3] 60	  
and the US Food and Drug Administration (FDA) [4] are strongly supporting the development of 61	  
alternative in vitro methods to implement the three Rs, that is “reduce, refine and replace” animal 62	  
models [5].  63	  
Hepatic cytochromes P450 are central to toxicological studies due to their primary role in phase I 64	  
metabolism of more than 80% of marketed drugs [6]. However to date, very little data is published 65	  
on comparative in vivo interspecies studies with even less data available on the different animal 66	  
P450 expression and/or their metabolic profile [7-10]. To this end, a fast and reliable in vitro 67	  
method would offer the possibility of a more detailed study of the interaction of new drugs with the 68	  
animal P450 enzymes therefore increasing the predictive value of these preclinical trials.  69	  
Canis familiaris is one of the most widely studied animal models used in safety determination of 70	  
new pharmaceuticals [11-12] and, although the major isoforms of the human cytochromes P450 71	  
2D6, 3A4, 2E1, 2C19 and 1A2 have been identified in C. familiaris [13-16], there is still a lack of 72	  
knowledge on their pharmacogenomic/metabolic diversity [9].  73	  
Electrochemical techniques already developed in our lab for human hepatic monooxygenases 74	  
including cytochromes P450 [17-22] represent the ideal approach for a sensitive, accurate and rapid 75	  
evaluation of animal P450-drug interactions obviating both the requirement for a redox partner and 76	  
the addition of NADPH cofactor as already reported for some animal P450 enzymes recombinantly 77	  
expressed in a soluble form [23-25]. 78	  
In this work, Canis familiaris P450 2D15 was chosen as a model for the investigation of canine 79	  
cytochromes P450 by adopting electrochemical approaches to provide a method for the screening of 80	  
the safety of new chemical entities/drugs. This enzyme shares 75% identity with the human 81	  
cytochrome P450 2D6 which alone is responsible for the metabolism of 20–25% of commonly used 82	  
therapeutic drugs including antiarhythmics, adrenoceptor antagonists, and tricyclic antidepressants 83	  
[6, 26]. The high P450 2D6 polymorphism profile is strictly related to either adverse drug reactions 84	  
or no drug response [26-27] and to date six different variants have been already identified in the 85	  
corresponding homologous C. familiaris P450 2D15 [28-30].  86	  
Generally, the study of the catalytic properties of canine P450 2D enzymes is hampered by the 87	  
difficulty in their preparation from liver microsomes [14] or by their recombinant expression and 88	  
purification in a stable form when not associated to the membranes [14-15, 28, 30]. To this end, in 89	  
this work we report for the first time the recombinant expression and purification of the Canis 90	  
familiaris P450 2D15 in a N-terminally modified form maintaining its structural integrity and 91	  
function. Furthermore, the electrocatalytic functionality of the purified enzyme is tested whilst 92	  
immobilized on glassy carbon electrodes (GC).  93	  
Two different immobilization strategies were adopted: a) entrapment within the cationic polymer 94	  
polydiallyldimethylammonium chloride (PDDA) (GC/PDDA/2D15); b) immobilization in presence 95	  
of gold nanoparticles (AuNPs) stabilized with didodecyldimethylammonium bromide (DDAB) 96	  
(GC/AuNPs/2D15). Gold nanoparticles are widely used in electrochemical applications [31] 97	  
especially because they act as excellent electron transfer relays by enhancing the electron transfer 98	  
from the electrode to the protein [32].  99	  
 100	  
Electrochemical properties of C. familiaris P450 2D15 immobilized on glassy carbon electrodes 101	  
were characterized by cyclic voltammetry and the activity of this enzyme in presence of metoprolol, 102	  
a selective β1 receptor blocker used in treatment of cardiovascular disease and a marker for human 103	  
P450 2D6 activity, assayed by chronoamperometry. The separation and identification of the product 104	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formed was carried out by HPLC leading to the calculation of the KM value of metoprolol for the 105	  
first time through the electrochemical system GC/AuNPs/2D15.  106	  
 107	  
 108	  
2 Material and methods 109	  
2.1 Reagents 110	  
Kits for plasmid and gene purification were purchased from Sigma Aldrich (Italy). Restriction 111	  
enzymes, T4 DNA ligase, Vent Polymerase and dNTPS were from New England Biolabs (UK). 112	  
Chromatographic resins were purchased from GE healthcare (Italy). Quinidine ((S)-[(2R,4S,5R)-5-113	  
ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol) and (±)-Metoprolol ({2-114	  
hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl}(propan-2-yl)amine) (+)-tartrate salt, racemic 115	  
mixture, were purchased from Sigma Aldrich (Italy). Analytical grade chemicals tetrachloroauric 116	  
(III) acid (gold(III) chloride), DDAB (didodecyl-dimethylammonium bromide) and PDDA 117	  
(poly(dimethyldiallylammonium chloride)) were all purchased from Sigma-Aldrich and their 118	  
solutions prepared prior to their use in appropriate solvent for electrochemical experiments.  119	  
 120	  
2.2 Cloning of recombinant P450 2D15 121	  
 122	  
The gene coding for cytochrome P450 2D15 was amplified from the liver cDNA of C. familiaris 123	  
(Biochain, UK) using the primers Fw: 5’-AGACAGCTATGGGGCTGCTG-3’ and Rv: 5’-124	  
TGGTTTATTGTACCTCGGGCC-3’. The entire gene was blunt end ligated into pBS SK II(+) 125	  
cloning vector using the EcoRV restriction enzyme. 126	  
Subsequently, the full-length cDNA coding for the canine P450 was cloned into a pCW expression 127	  
vector [33] fused in frame with the sequence coding for the leader peptide of the bacterial OmpA 128	  
protein (MKKTAIAIAVALAGFATVAQA). This system has been previously used to enhance the 129	  
expression of native mammalian cytochromes P450 in E. coli [14, 34]. This leader peptide is 130	  
cleaved in the bacterial membrane to yield the native P450 enzymes. A code of four histidine 131	  
residues was added at the C-terminus before the STOP codon to facilitate the protein purification by 132	  
affinity chromatography. 133	  
 134	  
2.3 Expression and purification of C. familiaris P450 2D15  135	  
 136	  
Large-scale expression (4 liters) of P450 2D15 in E. coli DH5α cells transformed with pCW- 2D15 137	  
was carried out as described previously for other P450 cytochromes [35] decreasing the post-138	  
induction expression time and temperature to 24 hours and 24 °C, respectively. 139	  
Purification of P450 2D15 was carried out starting from the isolated membrane fraction using an 140	  
anion exchange DEAE sepharose column (GE-healthcare, Italy) and followed by a nickel ion 141	  
affinity chromatography step (GE-healthcare, Italy) where the protein remained bound through the 142	  
engineered His-tag and subsequently eluted using a 0–40 mM linear gradient of histidine. In order 143	  
to preserve the P450 2D15 stability the protein was purified in presence of the human P450 2D6 144	  
inhibitor quinidine [36]. The UV-visible spectra of the oxidized, reduced and reduced-carbon 145	  
monoxide bound forms of the protein were recorded on a Hewlett-Packard 8453 diode array 146	  
spectrophotometer. The P450 concentration was calculated by the method described by Omura and 147	  
Sato [37]. 148	  
 149	  
2.4 Synthesis of AuNPs 150	  
 151	  
DDAB stabilized AuNPs were synthesized following the procedure described by Castrignanò et al. 152	  
in 2012 [32]. In particular, 0.5 mL of 10 mM tetrachloroauric (III) acid aqueous solution were 153	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mixed under vigorous stirring to 1 mL of a chloroform 0.1 M DDAB solution for 20 minutes to 154	  
allow the complete transfer of Au(III) ions from the aqueous to the chloroform. After the two 155	  
phases were separated, 0.2 mL of freshly prepared aqueous solution of 0.4 M sodium borohydride 156	  
were slowly added. After additional two hours of vigorous stirring, the red organic phase containing 157	  
the DDAB stabilized AuNPs was collected and stored at 4 °C before use. TEM morphological 158	  
characterization showed that the synthesized DDAB stabilized AuNPs mainly consist of spherical 159	  
particles of about 6.5-8.5 nm diameter, ranging from 2.5 to 13 nm in size. 160	  
 161	  
2.5 Immobilization of P450 2D15 on glassy carbon electrode and electrochemical measurements 162	  
 163	  
All electrochemical experiments were carried out at room temperature (25 °C) and in 50 mM 164	  
phosphate buffer pH 7.4, containing 100 mM KCl as supporting electrolyte, using an Autolab 165	  
PGSTAT12 potentiostat (Ecochemie, The Netherlands) controlled by GPES3 software. A 166	  
conventional three-electrode glass cell of 0.5 mL volume, equipped with a platinum wire counter 167	  
electrode, an Ag/AgCl (3 M NaCl) reference electrode and 3 mm diameter glassy carbon working 168	  
electrode (BASi., UK), was also used. Before enzyme immobilization, GC electrodes were 169	  
mechanically polished with alumina and subsequently rinsed and sonicated in ultra pure deionized 170	  
water. 171	  
The P450 2D15 enzyme was immobilized on glassy carbon (GC) with two different approaches: a) 172	  
P450 2D15 entrapment in PDDA film by mixing equal volumes of 30 µM protein and surfactant 173	  
solutions before drop-coating on the electrode surfaces (GC/PDDA/2D15); b) P450 2D15 174	  
immobilization on GC electrodes using didodecyldimethylammonium bromide (DDAB) stabilized 175	  
gold nanoparticles (AuNPs) (GC/AuNPs/2D15). 5 µl of 5 mM colloidal gold in 0.1 M 176	  
DDAB/chloroform was placed on the electrode surface. After evaporation of the chloroform (10 177	  
min), 10 µl of 30 µM P450 2D15 solution was added onto the electrode surface. The electrodes 178	  
were kept overnight at 4 °C in a humid chamber to prevent their total drying. 179	  
Cyclic voltammetry experiments were carried out under anaerobic conditions in a glove box with < 180	  
5 ppm oxygen (Belle Technologies, UK). Cyclic voltammograms were collected between +100 and 181	  
−500 mV (vs Ag/AgCl) at a scan rate range of 20–120 mVs−1 in the supporting electrolyte solution. 182	  
Electrocatalysis experiments were carried out using chronoamperometry applying a potential bias of 183	  
−650 mV (vs Ag/AgCl) or in cyclic voltammetry at 25°C in presence of metoprolol. The product 184	  
formed was separated and analyzed by HPLC as previously reported [38]. All electrocatalytic 185	  
experiments were carried out in triplicates and performed at 200 rpm rotation speed using a RDE-2 186	  
rotator system (BASi, USA). 187	  
 188	  
2.6 HPLC analysis of electrocatalysis products 189	  
 190	  
After chronoamperometry in the presence of metoprolol substrate, electrocatalysis solution was 191	  
collected and an aliquot of 100 µL was injected in HPLC for product quantification. 192	  
Electrocatalysis products were identified by comparison of retention times to those obtained with 193	  
authentic standards. For this purpose, standard solutions of metoprolol, α-OH-metoprolol and O-194	  
desmethyl-metoprolol were separated isocratically by HPLC (Agilent Technologies-1200 series, 195	  
Italy) coupled with diode array detector using a 4.6 × 150 mm 5 µm Eclipse XDB-C18 column 196	  
(Agilent Technologies, USA). Retention times were 3.8 min, 4.7 min and 10.5 min respectively for 197	  
α-OH-metoprolol, O-desmethyl-metoprolol and metoprolol. 198	  
 199	  
3. Results and discussion 200	  
3.1 Recombinant P450 2D15  201	  
 202	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The gene coding for the full length cytochrome P450 2D15 was amplified from Canis familiaris 203	  
liver cDNA and three mutations were identified by full DNA sequencing. A silent substitution of an 204	  
adenine in guanine was found 325 bases after the 2D15 start with two other mutations leading to the 205	  
amino acid substitutions of Ile109Val and Phe115Leu in the full-length protein (g345c and g738a). 206	  
Cytochromes P450 variants in C. familiaris 2D15 are not unusual and have been previously 207	  
reported [28-30] as they are a consequence of the genetic variability existing between dog colonies 208	  
[39]. 209	  
 210	  
“Here Figure 1” 211	  
 212	  
The gene encoding for the P450 2D15 variant with the three above-mentioned mutations was cloned 213	  
in the expression vector pCW and the OmpA leader peptide sequence was introduced at its N-214	  
terminus to enhance the protein expression levels as described in the materials and methods. The 215	  
protein was heterologously expressed in E. coli and purified from the membrane fraction with a 216	  
yield of 4.1 mg of P450 per liter of culture. Cytochrome P450 2D15 (57 kDa) (Fig.1A) was purified 217	  
in presence of quinidine, a known inhibitor of human P450 2D6. The purified protein was also 218	  
stored in the presence of this inhibitor which has been shown to preserve the stability of the protein 219	  
[36]. The inhibitor was removed prior to each experimental assay through buffer exchange. 220	  
Contrary to all previous literature data, in this work the purified C. familiaris P450 2D15 protein 221	  
and not the microsomal or membrane-associated protein was studied.   222	  
Binding of carbon monoxide to the dithionite reduced protein confirmed the presence of the 223	  
correctly incorporated haem cofactor inside the protein scaffold. The protein in its oxidized form 224	  
presents a Soret peak at 417 nm, the α and β bands at 570 nm and 535 nm, respectively (Fig.1B). As 225	  
expected, the Soret peak shows the characteristic shift to 450 nm upon reduction and bubbling of 226	  
carbon monoxide due to the reduced and carbon monoxide-bound adduct and the α and β bands are 227	  
replaced by a single broad peak centered at 550 nm as shown in Fig.1B. Similarly to the 228	  
microsomal P450 2D15 reported by Roussel and colleagues [29], a partial amount of inactive 229	  
protein was also detected at 420 nm (Fig.1B).  230	  
 231	  
3.2 Direct electrochemistry of P450 2D15 on glassy carbon electrodes 232	  
Recombinant P450 2D15 was immobilized on glassy carbon electrodes in a non-oriented fashion 233	  
either by entrapment within the cationic polymer polydiallyldimethylammonium chloride (PDDA) 234	  
(GC/PDDA/2D15) or in the presence of gold nanoparticles (AuNPs) (GC/AuNPs/2D15) which are 235	  
one of the most stable metal nanoparticles that provide an effective electron transfer to-and-from the 236	  
glassy carbon electrode [32, 40].  237	  
Once the protein was successfully immobilized on glassy carbon electrodes, cyclic voltammetry 238	  
experiments were carried out at 25°C under anaerobic conditions (< 5 ppm O2) to prevent the 239	  
formation of the Fe2+-dioxygen complex related to the second electron transfer step within the 240	  
catalytic cycle of cytochromes P450. Cyclic voltammograms of P450 2D15 entrapped with PDDA 241	  
(GC/PDDA/2D15) or in presence of AuNPs (GC/AuNPs/2D15) are shown in Fig.2A and B, 242	  
respectively. In both cases the ratio between the anodic and cathodic peak currents were found to be 243	  
one but the magnitude of the current observed was nearly 4x higher in the presence of AuNPs. As 244	  
stated by Laviron’s theory [41], the linear dependence of the anodic and cathodic peak currents on 245	  
the scan rate (within the range 20-120 mV) for both GC/PDDA/2D15 and GC/AuNPs/2D15, 246	  
indicated that the electron transfer from/to the modified GC electrode is quasi-reversible and it is a 247	  
surface-controlled process as expected for an immobilized cytochrome P450 on electrode surfaces.  248	  
 249	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“Here Figure 2” 250	  
 251	  
The resulting anodic and cathodic peak currents for GC/PDDA/2D15 were detected at −256±6 mV 252	  
(Ea) and −127±5 mV (Ec), respectively, with a calculated midpoint potential (Em) of -191±5 mV 253	  
(vs Ag/AgCl). In the GC/AuNPs/2D15 immobilization strategy, the anodic and cathodic peak 254	  
currents were measured at -267±5 mV (Ea) and −200±4 mV (Ec) (Fig.2D) and the resulting 255	  
midpoint potential was calculated to be -233±4 mV. These values are in the range of other 256	  
electrochemically determined midpoint potentials reported in the literature for different human 257	  
P450 enzymes [21].  258	  
Peak-to-peak separation value was calculated to be -129±6 for GC/PDDA/2D15 and -67±5 mV for 259	  
GC/AuNPs/2D15 indicating that the presence of the gold nanoparticles facilitates a much faster 260	  
electron transfer of P450 2D15 when immobilized on glassy carbon electrodes.  261	  
Apparent surface coverage of the electroactive protein was calculated from the slope of Ip versus n 262	  
plot in accordance with the Brown Anson model using the equation: 263	  
 264	  
ip = n2 F2 A G n/4RT 265	  
 266	  
where n represents the number of electrons involved in the reaction, A is the electrode surface area 267	  
(0.071 cm2), G is the surface coverage, n is the scan rate, F is the Faraday constant, T is the 268	  
temperature and R is the gas constant. The surface coverage value on GC/PDDA was calculated to 269	  
be 1.1X1012 molecules/cm2 in the same range previously reported for the Macaca fascicularis P450 270	  
2C20 immobilized in the same manner [25]. As expected the same calculation of the surface 271	  
coverage in the presence of AuNps resulted in a value of 4.6x1012 molecules/cm2, around 4 times 272	  
higher than using PDDA alone. 273	  
The electron transfer efficiency of the GC/AuNPs/2D15 was further investigated recording a series 274	  
of cyclic voltammograms varying the pH within the range 6.5< pH <8.5 (Fig. 3). A negative shift in 275	  
peak potential upon lowering pH was observed which is indicative of proton-coupled electron 276	  
transfer [42]. The measured shift in the formal potential was around 60 mV per pH unit, close to the 277	  
theoretical value of 59 mV/pH expected at 25°C for one proton, one electron transfer. The 278	  
protonation site of the reduced P450 remains unknown but it is reasonable to assume that it is either 279	  
an amino acid in close proximity of the haem iron or the water bound in the sixth coordination, as 280	  
has been suggested in the case of other cytochromes P450 [42-43]. Nocera’s group [44] have also 281	  
suggested that proton-coupled electron transfer in P450 enzymes is from a structured water, which 282	  
is the sixth coordinated H20 mentioned above.   283	  
 284	  
“Here Figure 3” 285	  
 286	  
 287	  
3.3 Electrocatalysis of 2D15 immobilized on glassy carbon electrodes 288	  
 289	  
Electrocatalysis by the immobilized P450 2D15 (GC/AuNPs/2D15) was followed by both 290	  
chronoamperometry and cyclic voltammetry in the presence of metoprolol. The latter drug (Scheme 291	  
1) is a cardioselective β1-adrenergic blocking agent metabolized principally by the human P450 292	  
2D6 and converted into the α-OH-metoprolol and O-desmethyl-metoprolol products [38]. The 293	  
amount of O-desmethyl-metoprolol (scheme1-left) after electrocatalysis was found to be below the 294	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detection limits. For this reason, only α-OH-metoprolol (scheme 1-right) was considered as a 295	  
product formed. 296	  
 297	  
“Here Scheme 1” 298	  
 299	  
As can be seen in Fig. 4A, a catalytic current was observed in air saturating conditions in the 300	  
presence of metoprolol in cyclic voltammetry experiments. Furthermore, using chronoamperometry 301	  
at regular internals additions of metoprolol were carried out in the range of 12.5-250 µM under 302	  
aerobic conditions (Fig. 4B) with an applied bias of -650 mV. The change in the 303	  
chronoamperometric currents registered due to the different concentrations of the drug showed a 304	  
Michaelis–Menten kinetic mechanism with a plateau or saturation at higher than 70µM 305	  
concentrations of metoprolol. The KMapp calculated from these currents was 39.5±3.5 µM (Fig. 5A). 306	  
 307	  
“Here Figure 4” 308	  
 309	  
Further electrocatalysis experiments were carried out by chronoamperometry for both the 310	  
GC/AuNPs/2D15 and the GC/PDDA/2D15 systems applying a potential bias of −650 mV (vs 311	  
Ag/AgCl) for 30 min at 25 °C in presence of different concentrations of metoprolol (Fig. 5B). For 312	  
each concentration of the drug tested, the contents of the electrochemical cell were analyzed after 313	  
the 30 min reaction by HPLC in order to separate and quantify the product(s) formed by the 314	  
immobilized enzyme. No products were detected from the HPLC analysis for the C. familiaris P450 315	  
2D15 enzyme entrapped with the polycationic agent PDDA. On the other hand, the enzyme 316	  
immobilized in the presence of AuNps (GC/AuNPs/2D15) was capable of hydroxylating the 317	  
metoprolol producing 30.7±2.3 pmol of product at the higher metoprolol concentrations used. No 318	  
O-desmethylated product was observed in line with previously published data on microsomal P450 319	  
2D15 [28].  320	  
 321	  
“Here Figure 5” 322	  
 323	  
Control experiments were also carried out in the absence of the protein and as expected no product 324	  
was detected (data not shown). Quantification of the reaction products in the presence of increasing 325	  
amounts of metoprolol (Fig. 5B) resulted in a calculated apparent KM value of 36.2±1.4 µM for 326	  
GC/AuNPs/2D15 (Table 1) very similar to the KMapp obtained by titrating different concentrations 327	  
of metoprolol (see Fig. 5A). The electrochemically determined KM values are also in the same range 328	  
as those reported by Ellis and colleagues for human P450 2D6 [45] therefore it can be concluded 329	  
that the C. familiaris P450 2D15 possesses similar enzymatic activity to human P450 2D6, at least 330	  
for metoprolol metabolism. 331	  
 332	  
“Here Table 1” 333	  
 334	  
4. Conclusions 335	  
The development of an electrochemical platform for the screening of animal cytochromes P450 336	  
represents an interesting and feasible solution to the ever increasing demand to reduce animal 337	  
testing, maintaining a high level of predictivity of the animal models used in preclinical tests and 338	  
providing the opportunity to study the P450 metabolism of new drugs and chemical entities. 339	  
To this end, the cloning of a new Canis familiaris P450 2D15 variant and its expression in a pure 340	  
form for its electrochemical application reported in this work, brings us a step closer to the 341	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realization of an in vitro electrochemical toxicity screening, an alternative to in vivo animal testing 342	  
and sacrifice.  343	  
The P450 2D15 enzyme was successfully immobilized on glassy carbon electrodes in a stable form 344	  
achieving an efficient electron transfer between the electrode and the enzyme. The presence of gold 345	  
nanoparticles enhanced the sensitivity of the electrode-protein system and allowed for the 346	  
estimation of kinetic parameters for metoprolol, a typical drug marker of the human P450 2D6.  347	  
These results represent the first step towards the development of electrochemical platform for the 348	  
rapid exploration of the metabolic diversity existing between animals and humans cytochromes 349	  
P450 contributing to a more reliable interpretation of the data generated in canine species during the 350	  
pharmacological preclinical studies. 351	  
 352	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Figure legends: 532	  
 533	  
Fig. 1: Purification and spectral characterization of P450 2D15. (A) SDS-PAGE gel, lane 1: 534	  
molecular weight markers, lane 2: purified protein (57 kDa). The absorbance spectra of the purified 535	  
P450 2D15 (B) in the oxidized (solid black line), dithionite reduced (dotted line), and the reduced 536	  
carbon monoxide-bound form (dashed line).    537	  
 538	  
Fig. 2: Electrochemical characterization of P450 2D15 immobilized on glassy carbon electrodes 539	  
(A) entrapped with the cathionic surfactant PDDA (GC/PDDA/2D15), and (B) in presence of gold 540	  
nanoparticles (GC/AuNPs/2D15). Cyclic voltammogram of P450 2D15 measured at a scan rate of 541	  
120 mV/s in 50 mM potassium phosphate buffer pH 7.4 with100 mM KCl at 25 °C. Shown are the 542	  
original and baseline corrected (upper traces) cyclic voltammograms. Bottom: plot of cathodic 543	  
(filled symbols) and anodic (empty symbols) peak currents versus scan rate. R2 > 0.99. 544	  
 545	  
Fig. 3: Cyclic voltammograms of GC/AuNPs/2D15 at a scan rate of 120 mVs−1 under anaerobic 546	  
conditions in different pH value buffer. The cyclic voltammogram at pH 7.4 is shown in black. 547	  
 548	  
Fig. 4: Electrochemical responses of GC/AuNPs/2D15 to metoprolol.  (A) Cyclic voltammograms 549	  
of the GC/AuNPs/2D15 in the air-saturated buffer in presence (black) and absence (grey) of 550	  
metoprolol shown together with control trace obtained in the absence of the protein (dashed); (B) 551	  
Chronoamperometric response of GC/AuNPs/2D15 at −650 mV followed for 600 sec in 50 mM 552	  
potassium phosphate buffer pH 7.4. The arrows indicate the addition of different concentrations of 553	  
metoprolol (12.5-250 µM). 554	  
 555	  
Fig. 5: Michaelis–Menten plot of the turnover of P450 2D15 immobilized on glassy carbon 556	  
electrode in presence of AuNps (GC/AuNPs/2D15) and metoprolol obtained from: (A) the current 557	  
registered in the titration experiments (Δ: current increase upon metoprolol addition) and, (B) 558	  
product quantified by HPLC after 30 min electrocatalysis. 559	  
 560	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